Download from app store
We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
story of the week
Published in Oncology

Journal Scan / Research · May 03, 2013

R-CHOP-21 Remains Standard First-Line Treatment in Patients With Diffuse Large B-Cell Lymphoma

The Lancet

 

Additional Info

Disclosure statements are available on the authors' profiles:

The Lancet
Rituximab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisolone in Patients With Newly Diagnosed Diffuse Large B-Cell Non-Hodgkin Lymphoma: A Phase 3 Comparison of Dose Intensification With 14-Day Versus 21-Day Cycles
Lancet 2013 Apr 22;[EPub Ahead of Print], D Cunningham, EA Hawkes, A Jack, et al

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading